Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Outros Autores: | , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Brazilian Journal of Otorhinolaryngology |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942009000500011 |
Resumo: | Allergic rhinitis affects 10-30% of the population, negatively impacting one's quality of life and productivity. It has been associated with sinusitis, otitis media, sleep disorders, and asthma. Rupatadine is a second generation antihistamine with increased affinity to histamine receptor H1; it is also a potent PAF (platelet-activating factor) antagonist. It starts acting quite quickly, offers long lasting effect, and reduces the chronic effects of rhinitis. AIM: this study aims to assess the efficacy and safety of rupatadine in the treatment of persistent allergic rhinitis. MATERIALS AND METHOD: this is a multi-centric open prospective study. This study included 241 patients from 13 centers in Brazil and was held between October of 2004 and August of 2005. Signs and symptoms of rhinitis and tolerance to medication were analyzed after one and two weeks of treatment. RESULTS: reduction on general scores from 8.65 to 3.21 on week 2 (p<0.001). All signs and symptoms improved significantly in the first day of treatment (p<0.001), except for nasal congestion and secretion, which improved from the second day of treatment (p<0.001). Adverse events occurred in 19.9% of the cases, 27.7% on week 1. CONCLUSION: rupatadine effectively controls persistent allergic rhinitis; it is safe and presents low incidence of side effects. |
id |
ABORL-F-1_5b4cfda6b7774123b2a2497e8c6fe4ed |
---|---|
oai_identifier_str |
oai:scielo:S1808-86942009000500011 |
network_acronym_str |
ABORL-F-1 |
network_name_str |
Brazilian Journal of Otorhinolaryngology |
repository_id_str |
|
spelling |
Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitisperennial allergic rhinitistherapyAllergic rhinitis affects 10-30% of the population, negatively impacting one's quality of life and productivity. It has been associated with sinusitis, otitis media, sleep disorders, and asthma. Rupatadine is a second generation antihistamine with increased affinity to histamine receptor H1; it is also a potent PAF (platelet-activating factor) antagonist. It starts acting quite quickly, offers long lasting effect, and reduces the chronic effects of rhinitis. AIM: this study aims to assess the efficacy and safety of rupatadine in the treatment of persistent allergic rhinitis. MATERIALS AND METHOD: this is a multi-centric open prospective study. This study included 241 patients from 13 centers in Brazil and was held between October of 2004 and August of 2005. Signs and symptoms of rhinitis and tolerance to medication were analyzed after one and two weeks of treatment. RESULTS: reduction on general scores from 8.65 to 3.21 on week 2 (p<0.001). All signs and symptoms improved significantly in the first day of treatment (p<0.001), except for nasal congestion and secretion, which improved from the second day of treatment (p<0.001). Adverse events occurred in 19.9% of the cases, 27.7% on week 1. CONCLUSION: rupatadine effectively controls persistent allergic rhinitis; it is safe and presents low incidence of side effects.Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial.2009-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942009000500011Brazilian Journal of Otorhinolaryngology v.75 n.5 2009reponame:Brazilian Journal of Otorhinolaryngologyinstname:Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)instacron:ABORL-CCF10.1590/S1808-86942009000500011info:eu-repo/semantics/openAccessMion,Olavo de GodoyCampos,Regis A.Antila,MarttiRapoport,Priscila BogarRosario,NelsonMello Junior,João Ferreira deGuimarães,Roberto Eustáquio SantosMocellin,MarcosDi Gesu,GiovanniSolé,DirceuWexler,LucMello,João Ferreira deCastro,Fábio MoratoChavarria,Maria Letíciaeng2009-11-03T00:00:00Zoai:scielo:S1808-86942009000500011Revistahttp://www.bjorl.org.br/https://old.scielo.br/oai/scielo-oai.phprevista@aborlccf.org.br||revista@aborlccf.org.br1808-86861808-8686opendoar:2009-11-03T00:00Brazilian Journal of Otorhinolaryngology - Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF)false |
dc.title.none.fl_str_mv |
Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis |
title |
Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis |
spellingShingle |
Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis Mion,Olavo de Godoy perennial allergic rhinitis therapy |
title_short |
Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis |
title_full |
Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis |
title_fullStr |
Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis |
title_full_unstemmed |
Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis |
title_sort |
Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis |
author |
Mion,Olavo de Godoy |
author_facet |
Mion,Olavo de Godoy Campos,Regis A. Antila,Martti Rapoport,Priscila Bogar Rosario,Nelson Mello Junior,João Ferreira de Guimarães,Roberto Eustáquio Santos Mocellin,Marcos Di Gesu,Giovanni Solé,Dirceu Wexler,Luc Mello,João Ferreira de Castro,Fábio Morato Chavarria,Maria Letícia |
author_role |
author |
author2 |
Campos,Regis A. Antila,Martti Rapoport,Priscila Bogar Rosario,Nelson Mello Junior,João Ferreira de Guimarães,Roberto Eustáquio Santos Mocellin,Marcos Di Gesu,Giovanni Solé,Dirceu Wexler,Luc Mello,João Ferreira de Castro,Fábio Morato Chavarria,Maria Letícia |
author2_role |
author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Mion,Olavo de Godoy Campos,Regis A. Antila,Martti Rapoport,Priscila Bogar Rosario,Nelson Mello Junior,João Ferreira de Guimarães,Roberto Eustáquio Santos Mocellin,Marcos Di Gesu,Giovanni Solé,Dirceu Wexler,Luc Mello,João Ferreira de Castro,Fábio Morato Chavarria,Maria Letícia |
dc.subject.por.fl_str_mv |
perennial allergic rhinitis therapy |
topic |
perennial allergic rhinitis therapy |
description |
Allergic rhinitis affects 10-30% of the population, negatively impacting one's quality of life and productivity. It has been associated with sinusitis, otitis media, sleep disorders, and asthma. Rupatadine is a second generation antihistamine with increased affinity to histamine receptor H1; it is also a potent PAF (platelet-activating factor) antagonist. It starts acting quite quickly, offers long lasting effect, and reduces the chronic effects of rhinitis. AIM: this study aims to assess the efficacy and safety of rupatadine in the treatment of persistent allergic rhinitis. MATERIALS AND METHOD: this is a multi-centric open prospective study. This study included 241 patients from 13 centers in Brazil and was held between October of 2004 and August of 2005. Signs and symptoms of rhinitis and tolerance to medication were analyzed after one and two weeks of treatment. RESULTS: reduction on general scores from 8.65 to 3.21 on week 2 (p<0.001). All signs and symptoms improved significantly in the first day of treatment (p<0.001), except for nasal congestion and secretion, which improved from the second day of treatment (p<0.001). Adverse events occurred in 19.9% of the cases, 27.7% on week 1. CONCLUSION: rupatadine effectively controls persistent allergic rhinitis; it is safe and presents low incidence of side effects. |
publishDate |
2009 |
dc.date.none.fl_str_mv |
2009-10-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942009000500011 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1808-86942009000500011 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S1808-86942009000500011 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. |
publisher.none.fl_str_mv |
Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. |
dc.source.none.fl_str_mv |
Brazilian Journal of Otorhinolaryngology v.75 n.5 2009 reponame:Brazilian Journal of Otorhinolaryngology instname:Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF) instacron:ABORL-CCF |
instname_str |
Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF) |
instacron_str |
ABORL-CCF |
institution |
ABORL-CCF |
reponame_str |
Brazilian Journal of Otorhinolaryngology |
collection |
Brazilian Journal of Otorhinolaryngology |
repository.name.fl_str_mv |
Brazilian Journal of Otorhinolaryngology - Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial (ABORL-CCF) |
repository.mail.fl_str_mv |
revista@aborlccf.org.br||revista@aborlccf.org.br |
_version_ |
1754575988515143680 |